香港, 2024年12月4日 - (亚太商讯 via SeaPRwire.com) - 中信国际电讯集团有限公司（「中信国际电讯」，香港交易所股份代号：1883）全资拥有的中信国际电讯(信息技术) 有限公司(「中信国际电讯CPC」) 宣布勇夺三项业界大奖 ，肯定中信国际电讯CPC深耕网络安全的优质表现，表扬专业团队深厚的行业知识与技术、员工高度的网络安全意识及前瞻的创新解决方案，以满足市场对不断增长的网络安全需求 ，应对日益猖獗的网络威胁和挑战。三项业界大奖包括:- 香港互联网注册管理有限公司(HKIRC)「共建员工防火墙」嘉许计划2024 白金级奖 ；- Fortinet「2024年度最佳托管安全服务供应商」奖项 (Top MSSP of the Year 2024)；- Green Radar 「2024 年度最佳企业业务合作伙伴」奖项 (Top Partner Enterprise Business FY24 )中信国际电讯 CPC 行政总裁黄政华先生表示：「该三项业界大奖展示我们对推动内部'员工防火墙'文化的承诺，同时通过我们的网络安全专家团队向企业客户提供全面的解决方案，彰显了我们在内外实力上的坚实基础。业界对我们的肯定将激励我们持续提升网络安全创新方案，期望带来更多的市场机遇，共同推动行业的高质量发展。我们有信心，旗舰信息安全解决方案'TrustCSI™ 3.0云网神盾'在网络安全市场保持优势竞争力，巩固我们作为前沿网络安全领导者地位。」 HKIRC「共建员工防火墙」嘉许计划香港互联网注册管理有限公司 (HKIRC) 与国际信息系统审计协会中国香港分会 (ISACA) 联合举办的「共建员工防火墙」嘉许计划圆满举行 ，参加机构涵盖了银行、物业管理、零售等行业的中小企及大型企业。该计划旨在表彰得奖企业在过去一年内意识到网络安全重要性并积极提升员工网络安全意识的努力。「共建员工防火墙」嘉许计划鼓励更多机构采取积极的措施推广「员工防火墙（Human Firewall）」理念 ，通过多种渠道如培训、政策、沟通、演习等提高员工防护意识。最高级别白金级奖需要符合所有5项评审标准，包括网络安全培训 、网络钓鱼演习 、网络安全政策 、通报渠道及网络安全资讯传递 。中信国际电讯CPC 荣获最高级别之白金级认证，表扬其致力过去不但在网络安全技术上不断提升、在系统和政策方面全面优化，并推出'TrustCSI™ 3.0 云网神盾'信息安全服务，创新的服务框架，配备主动防御技术以应对快速迭代的网络威胁。 同时培养员工对网络安全意识文化的决心，通过全球员工强度训练及网络安全演练，构建为公司的第二道防线，防范并能有效应对不断变化的网络威胁。 共创共赢， 构建更坚固的防御生态圈此外，中信国际电讯CPC 荣获两家网络安全服务生态圈伙伴Fortinet及Green Radar颁发多个卓越奖项，彰显其在全球性合作策略和网络安全领域高质量的协作能力，通过持续的技术创新和与生态圈合作伙伴的紧密合作，中信国际电讯CPC得以不断提升产品和服务质量，以满足市场对网络安全方案的需求并超越竞争对手。其中包括在 2023 年推出的 TrustCSI™ 3.0 云网神盾，通过智能技术重塑安全运营中心（SOC）的核心服务能力，为企业提供主动式防御，将AI 应用融入其业务中，优化智能运营。首先， Fortinet颁发的「2024 年度最佳托管安全服务供应商」奖项肯定了中信国际电讯CPC 前沿的托管安全服务，超越业界标准。另外，Green Radar「2024 年度最佳企业业务合作伙伴」奖项表扬中信国际电讯CPC与合作伙伴携手推动创新解决方案，以满足企业客户独特的网络安全需求。积极提升内外网络安全及创新技术中信国际电讯CPC无论对内或对外，一直积极展现高水平的网络安全能力。在对内方面，中信国际电讯CPC致力培育员工网络安全意识，而员工在工作上时刻保持警惕和采用主动的防御措施，体现了对网络安全的最佳实践，以保护公司的数资产。在对外方面，中信国际电讯CPC致力成为企业可信赖的TechOps 信息安全赋能者，旗下的网络安全专家团队具备前瞻思维和追求卓越成就的精神，通过专业服务和创新定制的解决方案，助力客户轻松及灵活地应对瞬息万变的数字环境。秉持'创新不断'服务理念，中信国际电讯CPC持续将人工智能技术整合到信息安全产品组合中，提供前沿网络安全解决方案以应对愈发猖獗的网络威胁。中信国际电讯CPC最新的TrustCSI AI渗透测试(AI Pentest)服务如同网络AI扫地机器人，7x24全自动化工作，协助企业找出网络中的致命漏洞，建立强大的防御机制 。为了强化企业客户内外部的漏洞，中信国际电讯CPC特别提供了一个最新内外评估组合方案，协助客户通过对内的AI渗透测试服务，同时，进行攻击面管理 (Attack Surface Management)，增强公司对外部漏洞的抵御能力，并系统地优化漏洞识别、排列漏洞优次、补救和持续监控等攻击，通过多管齐下的防护措施降低潜在的网络攻击风险，提升企业安全管理策略。详情可浏览https://www1.citictel-cpc.com/promotion/2411XmasOffer/index-SC.html中信国际电讯CPC简介中信国际电讯（信息技术）有限公司（「中信国际电讯CPC」）是中信国际电讯集团有限公司（香港交易所股份代号：1883）的全资附属公司，公司一直矢志透过先进技术及旗舰解决方案，包括TrueCONNECT专用网络服务、TrustCSI信息安全解决方案、DataHOUSE全球统一云数据中心解决方案及SmartCLOUD云端运算解决方案，为全球跨国企业提供综合数码解决方案， 满足不同行业的ICT服务需求。凭借「创新-不断」的服务理念，中信国际电讯CPC积极利用创新技术，提炼'技术赋能'，将人工智能、扩增实境、大数据、物联网和其他尖端新兴技术，融合深度学习及智能数据分析技术，转化为'数据赋能'生成式AI+应用，重塑企业智能营运之旅。中信国际电讯CPC以「服务在地，连接全球」优势，承诺为客户提供优质的一站式ICT服务。全球化网络资源连接近170个服务据点、60多个SDWAN 网关；21个云服务中心、30多个数据中心及3个全天候运作的安全运作中心，服务遍布约160个国家和地区，无缝连接亚洲、欧美、非洲、中东以及中亚等地区。透过全球化服务布局，多年不断深耕各个行业与领域经验，一系列国际标准服务认证（SD-WAN Ready, ISO 9001、14001、20000、27001 及27017），确保为企业提供国际化标准及服务资源，专业的在地服务及交付能力，同时，优质的客户体验和服务质量，成为领先的综合信息智能化服务供应商。请浏览www.citictel-cpc.com 获取更多资讯。传媒查询：Catherine Yuen中信国际电讯CPC(852) 2170 7536电邮：catherine.yuen@citictel-cpc.com Copyright 2024 亚太商讯 via SeaPRwire.com.

MUNICH, GERMANY | DRESDEN, GERMANY | TEL AVIV, ISRAEL, Dec 4, 2024 - (ACN Newswire via SeaPRwire.com) - Autobrains, a leader in automotive artificial intelligence (AI), has joined forces with JOYNEXT, a global automotive Tier-1 supplier and development partner to renowned car manufacturers for over 20 years, to offer their groundbreaking Smart Camera ADAS solution. The camera hardware and optimized control software, provided by JOYNEXT, is powered by Autobrains' Affordable Safety ADAS software. The single-box Smart Camera solution, optimized for cost-effective Advanced Driver Assistance Systems (ADAS), was designed to meet the evolving needs of global Original Equipment Manufacturers (OEMs). This compact system simplifies integration, reduces costs, and ensures regulatory compliance without sacrificing performance.With ever increasing global regulations, smart cameras are a must-have in new build vehicles. The joint Smart Camera meets stringent global safety standards, including Europe's General Safety Regulation (GSR) and Euro NCAP requirements, ensuring its readiness for widespread deployment across vehicle classes. "Building a powerful ecosystem is crucial in order to be able to offer our global customers reliable and future-oriented technologies," says Stavros Mitrakis, CEO of JOYNEXT GmbH. "Autobrains is a fitting partner. With them, we will be able to offer reliable, high-quality, and cost-effective technologies in the field of automated driving in the future."Affordable Safety AI Software"Our new Affordable Safety ADAS solution leverages Autobrains' signature-based self-learning Liquid AI technology, delivering unparalleled efficiency and significantly lowering training, validation, and BOM (Bill of Materials) costs," explains Igal Raichelgauz, Founder and CEO of Autobrains. "By indexing and compressing data into sparse binary representations, the AI system requires less computational power, reducing the size and cost of the SoC (System-on-Chip) and sensor needed for operation." Autobrains' Liquid AI mimics human brain functionality, reducing reliance on labeled data, accelerating development cycles, and minimizing data bias. This hardware-agnostic solution offers OEMs the flexibility to integrate it into existing hardware environments, making ADAS accessible to a wider range of vehicles, from premium models to compact cars, without compromising safety or performance.ADAS as a Standard FeatureDriver assistance systems are becoming standard in all vehicle segments and regions thanks to stronger regulations and NCAP safety ratings. "Providing these assistance systems cost-efficiently to car manufacturers and drivers is a challenge for the industry," says Manuel Yoon, General Manager Germany and VP Strategy of Autobrains. "Our contribution is to help reduce the number of accidents by providing technology that enables autonomous emergency braking, lane-keeping support, and intelligent speed assistants for everyone. In addition, we can reduce the drivers' burden with comfort features such as adaptive cruise control with a single camera."Streamlined ScalabilityThe system eliminates the need for complex multi-component systems, reducing time-to-market while enhancing scalability. "Our smart camera combines data collection, processing and control in one compact device. There are expansion stages with an additional interior camera, which means the system can also meet driver monitoring requirements within a single module. This makes our products an attractive solution, especially for European and Asian OEMs." emphasizes Jan Kolanko, Senior Manager for ADAS at JOYNEXT GmbH.The new Smart Camera ADAS solution will be available for OEMs worldwide starting in early 2025. This groundbreaking solution aims to democratize advanced safety technologies, making them accessible to a broader range of vehicles and markets.For more information about Autobrains and its innovative AI solutions, please visit www.autobrains.ai.Autobrains - We Drive AIAutobrains is a leading AI company in the automotive industry. Autobrains invented and developed a paradigm-shifting AI technology: Liquid AI - backed by 250+ patents addressing autonomous driving challenges. Implementing this unique AI technology for ADAS applications disrupts the market with its unprecedented perception capabilities, low compute requirements, and agnosicity to sensors and SoCs. The company is backed by strategic investors including Temasek, Knorr-Bremse, BMW i Ventures, Toyota Ventures, VinFast, Continental, and Autel.JOYNEXT - WE CONNECT FUTUREIntelligent solutions for connected vehicles - that's JOYNEXT. We are working on future technologies that are becoming increasingly important for car manufacturers and their customers. On the road to autonomous driving, data communication between the vehicle and mobile devices such as smartphones, with other vehicles (V2V) or with infrastructure systems (V2I) is becoming increasingly important. JOYNEXT is also involved in the new and further development of cloud-based services.JOYNEXT always strives for a balance between innovation and sustainability. When developing our products, we focus on the end user and their needs and usage behavior.With more than 1,500 employees worldwide, JOYNEXT takes connected car technologies to a new level. We are present at seven locations; our development and innovation centers are located in Dresden (Germany) and Ningbo (China).JOYNEXT is a direct supplier to the automotive industry and has been a development partner and system supplier to renowned car manufacturers for over 20 years. Our technologies in the areas of connected infotainment and smart connectivity gateways can be found in millions of vehicles worldwide. www.JOYNEXT.comContact InformationSophia EichlerDirector of Marketingmedia@autobrains.ai+49 15167066494Source: Autobrains Copyright 2024 ACN Newswire via SeaPRwire.com.

HONG KONG, Dec 4, 2024 - (ACN Newswire via SeaPRwire.com) – CITIC Telecom International CPC Limited (“CITIC Telecom CPC”), a wholly-owned subsidiary of CITIC Telecom International Holdings Limited (SEHK: 1883) is pleased to announce the winning of three industry awards, affirming CITIC Telecom CPC’s unwavering commitment to cybersecurity excellence, recognizing the deep industry expertise of its professional team, strong cybersecurity awareness among its workforce and cutting-edge innovative solutions to meet the growing cybersecurity demand and combat the increasingly rampant cyber threats and challenges.The three industry awards are:- Hong Kong Internet Registration Corporation Limited (HKIRC) - Platinum Award in Cyber Security Staff Awareness Recognition Scheme 2024;- Top Managed Security Service Provider (MSSP) of the Year 2024, by Fortinet;- Top Partner Enterprise Business FY24, by Green RadarMr. Brook Wong, Chief Executive Officer of CITIC Telecom CPC, said, “The three industry accolades are a testament to our commitment to foster internal ‘Human Firewall’ culture in our company while providing cutting-edge security solutions externally through our cybersecurity experts, showcasing our solid foundation in both internal and external cybersecurity excellence. These industry recognitions inspire us to further elevate cybersecurity awareness and innovative solutions, unleashing more market opportunities and jointly nurturing high-quality industry development. We lead the market with our dedicated approach to promoting advanced security solutions "TrustCSI™ 3.0", solidifying our position as a cybersecurity leader in digital defense.” HKIRC Cyber Security Staff Awareness Recognition SchemeCo-organized by The Hong Kong Internet Registration Corporation Limited (HKIRC) and ISACA China Hong Kong Chapter (ISACA), Cyber Security Staff Awareness Recognition Scheme was completed. Participating organizations include SMEs and large enterprises in banking, property management, retail and other industries. The Scheme aims to recognize organizations that are aware of the importance and have implemented suitable measures to enhance cybersecurity staff awareness within their organizations in the past 12 months. The Scheme enhances organizations’ protection level by encouraging the organizations to promote “Human Firewall” concept through multiple channels such as training, policy, communication, drill, etc. The top-tier Platinum Award requires the fulfilment of all the five assessment criteria including cybersecurity training, phishing drill participation, comprehensive cybersecurity policy, reporting channels for cybersecurity issues and dissemination of cybersecurity information.CITIC Telecom CPC has clinched the prestigious Platinum Award in recognition of its dedication to enhancing network security technologies, comprehensive optimiziation of systems and policies, and the introduction of "TrustCSI™ 3.0" cybersecurity solution, innovative service framework and proactive defense technologies to respond to ever-increasing network threats. CITIC Telecom CPC also cultivates a culture of cybersecurity awareness among its staff through global staff training and cybersecurity drills, building a second level of defense line for the company to defend and effectively address ever-changing security threats. Collaborate to Succeed: Building a Robust Defense EcosystemsCITIC Telecom CPC achieved various prestigious awards from two cybersecurity ecosystem partners Fortinet and Green Radar, demonstrating its excellent collaboration capabilities in global cooperation strategies and cybersecurity. CITIC Telecom CPC has not only met the market demand for cybersecurity solutions, but also surpassed competitors through continuous technological innovations and close collaborations with ecosystem partners, including the launch of "TrustCSI™ 3.0" cybersecurity solutions in 2023, which enhances the core service capabilities of the Security Operations Center (SOC) to provide enterprises with proactive defense, integrate AI applications into their business, and optimize their intelligent operations.CITIC Telecom CPC has been bestowed "Top Managed Security Service Provider of the Year 2024" by Fortinet, a testament to the company's excellence in providing cutting-edge managed security services that exceed industry standards. In addition, CITIC Telecom CPC has been recognized as the "Top Partner Enterprise Business FY24" by Green Radar, which underscores CITIC Telecom CPC's strategic collaborations with partners to provide innovative solutions to address unique cybersecurity needs of enterprise clients.Proactively Elevating Network Security and Innovative Technologies Internally and ExternallyCITIC Telecom CPC actively pursues excellent cybersecurity capabilities, both internally and externally. Internally, CPC fosters a culture of cybersecurity awareness. Its staff have demonstrated cybersecurity best practices by always staying vigilant and employing proactive defense in the workplace, thus safeguarding the company’s digital assets. Externally, CITIC Telecom CPC is committed to be a trusted TechOps Security Enabler for enterprises. With a passion for innovation and excellence, its cybersecurity experts team provides professional services and tailored innovative solutions, empowering enterprises to navigate the digital landscape with confidence and resilience.With the motto “Innovation Never Stops”, CITIC Telecom CPC continues to integrate AI technology into its information security products portfolio to provide advanced cybersecurity solutions for addressing the evolving network threats. The newly-launched TrustCSI™ AI Pentest service functions as an AI robot cleaner which automatically operates 24x7, helping enterprises identify key vulnerabilities in the network and establish a robust defense against potential threats. CITIC Telecom CPC introduces a special offer which includes TrustCSI™ AI Pentest and Attack Surface Management (ASM) for internal and external vulnerabilities scanning, enhancing customers’ resistance to vulnerabilities and systematically improving identification, prioritization and remediation of vulnerabilities, and continuous monitoring of hacking attempts. Enterprise security management strategy can be elevated through multiple defense measures to mitigate potential network attack risks. For special offer details, please visit https://www1.citictel-cpc.com/promotion/2411XmasOffer/index-EN.html.About CITIC Telecom CPCWe are CITIC Telecom International CPC Limited (“CITIC Telecom CPC”), a wholly-owned subsidiary of CITIC Telecom International Holdings Limited (SEHK: 1883), serving multinational enterprises the world over by addressing their specific ICT requirements with highly scalable tailored solutions built upon our flagship technology suites, comprising TrueCONNECT™ private network solutions, TrustCSI™ information security solutions, DataHOUSE™ cloud data center solutions, and SmartCLOUD™ cloud computing solutions.With the motto “Innovation Never Stops,” we leverage innovative technologies to boost technology empowerment (+AI). Embracing AI, AR, Big Data, IoT, and other cutting-edge emerging technologies we aim to unlock technical potential. By integrating deep learning and intelligent data analysis technologies, we transform these technologies into data empowerment (AI+) generative applications, reshaping the Intelligence Operation Journey of enterprises.With our Global-Local capabilities, we are committed to providing our customers with one-stop-shop ICT solutions with superior quality. Having a worldwide footprint across nearly 160 countries and regions, including Asia, Europe and America, Africa, the Middle East, and Central Asia, our global network resources connect nearly 170 points of presence (POPs), 60+ SDWAN gateways, 21 Cloud service centers, 30+ data centers, and three dedicated 24x7 Security Operations Centers (SOCs). We are certified with a series of international certifications, including SD-WAN Ready, ISO 9001, 14001, 20000, 27001, and 27017, to ensure our services compliance with international standards and resources for enterprises. We offer local professional services, superior delivery capabilities as well as exceptional customer experience and best practices through our global presence and extensive industry know-how, becoming a leading integrated intelligent ICT service provider to enterprise customers. For more information, please visit www.citictel-cpc.com.Media Contacts:Catherine YuenCITIC Telecom CPC(852) 2170 7536Email: catherine.yuen@citictel-cpc.com Copyright 2024 ACN Newswire via SeaPRwire.com.

- 在已完成36周治疗的低剂量组患者中，81.8%（9/11）的患者实现临床缓解，高剂量组中已完成24周治疗的患者已有85.7%（6/7）实现临床缓解。- 除低剂量组的1例患者外，其他所有完成36周治疗的低剂量组患者，以及所有经24周治疗的高剂量组患者分别在36周和24周都实现了免疫学完全缓解。- EVER001总体安全性和耐受性良好。未见在其他共价非可逆BTK抑制剂上观察到的有临床意义的不良事件，如出血、心律失常、严重感染、白细胞减少、血小板减少、严重肝功能损伤等。上海, 2024年12月4日 - (亚太商讯 via SeaPRwire.com) - 云顶新耀（HKEX 1952.HK）是一家专注于创新药研发、临床开发、制造和商业化的生物制药公司，今日宣布新一代共价可逆布鲁顿酪氨酸激酶（BTK）抑制剂 EVER001胶囊（又名：XNW1011）在治疗原发性膜性肾病（primary membranous nephropathy，pMN）的1b/2a期临床试验阶段性数据取得积极结果。直至9月13日的数据截止日期，结果显示，在已完成36周治疗的低剂量组患者中，81.8%（9/11）的患者实现临床缓解，高剂量组中已完成24周治疗的患者已有85.7%（6/7）实现临床缓解。除低剂量组的1例患者外，其他所有完成36周治疗的低剂量组患者，以及所有经24周治疗的高剂量组患者分别在36周和24周都实现了免疫学完全缓解。EVER001是一款适用于自身免疫性肾脏疾病的共价可逆BTK抑制剂。与共价不可逆BTK抑制剂相比，EVER001作为一款潜在的同类最佳产品，在保持高活性的同时具有高选择性，避免持续抑制带来的毒副作用。云顶新耀拥有这款产品用于肾病治疗的全球权益。EVER001治疗原发性膜性肾病的1b/2a期临床试验为一项正在进行中的中国研究。共有31名经肾脏活检证实的抗-PLA2R自身抗体阳性的原发性膜性肾病患者分别入组低剂量组和高剂量组，接受EVER001 共36周的治疗。截至2024年9月13日的数据分析，低剂量组的24小时蛋白尿几何平均值（最小二乘法）在36周相较于基线下降78.3%，而高剂量组在24周即出现73.8%的下降。抗-PLA2R自身抗体水平在数据截止日期时已达到接近100%的下降，而早在低剂量组的24周和高剂量组的12周，抗-PLA2R自身抗体下降已超过90%。EVER001总体安全性和耐受性良好。未见在其他共价非可逆BTK抑制剂上观察到的有临床意义的不良事件，如出血、心律失常、严重感染、白细胞减少、血小板减少、严重肝功能损伤等。云顶新耀首席执行官罗永庆表示："非常高兴看到EVER001在此次公布的阶段性数据中取得了积极的结果。这显示了EVER001作为新一代BTK抑制剂，对包括原发性膜性肾病在内的多种自身免疫性肾病治疗的巨大潜力。迄今为止，全球没有获批原发性膜性肾病适应症的药物。作为首个公布的具有全球权益的管线产品数据，EVER001在原发性膜性肾病患者中取得的阶段性结果令人鼓舞。我们也期待该1b/2a期临床试验的完成及更多相关数据的发表。我们将继续推进EVER001的全球临床开发，以最快速度满足患者的临床需求。"膜性肾病为成人肾病综合征常见的病理类型，在我国的患病率呈逐年升高的趋势，是发病率仅次于IgA肾病的原发性肾小球肾炎1。我国目前有约200万原发性膜性肾病患者，而在美国约有8万-10万患者，欧洲约8万患者，日本约4万患者。目前全球没有获批此适应症的药物。超过1/3的原发性膜性肾病患者最终将进展为终末期肾病，全球亟需研发能提高治疗缓解率、降低高复发率、减少慢性肾毒性风险的治疗药物。此项1b/2a期临床试验于2022年9月获得中国国家药品监督管理局药品审评中心批准，用于评价EVER001在蛋白尿为特征的肾小球疾病的中国患者中的安全性、疗效、药代动力学和药效学。此前公布的中国抗体制药在中国健康受试者中进行的1期研究结果表明，EVER001具有高选择性、优异的药代动力学特征、良好的安全性特征以及强大的靶点结合力。关于EVER001EVER001胶囊（又名：XNW1011）是新一代共价可逆的布鲁顿酪氨酸激酶 （BTK）抑制剂，正在全球范围内开发用于治疗肾病。BTK是B 细胞受体信号通路的重要组成部分，可调节 B 淋巴细胞的存活、激活、增殖和分化。应用小分子抑制剂靶向 BTK 是治疗 B 细胞淋巴瘤和自身免疫性疾病的有效选择。中国抗体制药在国内完成的健康受试者I期研究结果表明，EVER001具有高选择性、优异的药代动力学特征、强大靶点结合力和良好的安全性特征，研究结果支持其进一步临床开发。根据与信诺维医药和中国抗体制药的独家许可协议，云顶新耀拥有在全球开发、生产和商业化EVER001用于治疗肾病的权利。投资人会议公司将举行中英文投资人线上会议，公布新一代共价可逆布鲁顿酪氨酸激酶（BTK）抑制剂 EVER001胶囊治疗原发性膜性肾病的1b/2a期临床试验数据。云顶新耀拥有EVER001在全球范围内开发用于治疗肾病领域的权益。英文场次将于北京时间2024年12月4日上午9时（美国东部时间12月3日晚上8时）举行；中文场次将于北京时间同日上午10:30时（美国东部时间12月3日晚上9:30时）举行。英文会议：会议时间：北京时间2024年12月4日，星期三，上午9时（美国东部时间12月3日晚上8时）提前注册链接：https://www.acecamptech.com/eventDetail/60510700会议直播链接：https://www.acecamptech.com/meeting_live/70512679/774680?event_id=60510700同时，参会者也可以使用以下拨入信息拨入电话会议：美国：+1-646-2543594 (EN)中国大陆：+86-10-58084166 (EN)，+86-10-58084199 (CN)中国香港：+852-30051313 (EN)，+852-30051355 (CN)英国：+44-12-1368-0466 (EN)国际：+1-866-6363243 (EN)会议代码：842080中文会议：会议时间：北京时间2024年12月4日，星期三，上午10:30时（美国东部时间12月3日晚上9:30时）会议直播链接： https://s.comein.cn/n3arj55s同时，参会者也可以使用以下拨入信息拨入电话会议：美国:+1-646-3578788，+1-408-7093255中国大陆:400-969-8928，400-806-3263中国香港:+852-301-83602中国台湾:+886-226563394，+886-277417882新加坡:+65-64075649，+65-66220840英国:+44-2070970018海外:+86-2362737123会议密码:377570英文会议结束后，您可以通过访问云顶新耀官网（http://www.everestmedicines.com）收听英文会议回放。关于云顶新耀云顶新耀是一家专注于创新药和疫苗研发、临床开发、制造和商业化的生物制药公司，致力于满足亚洲市场尚未满足的医疗需求。云顶新耀的管理团队在中国及全球领先制药企业从事过高质量研发、临床开发、药政事务、化学制造与控制（CMC）、业务发展和商业化运营，拥有深厚的专长和丰富的经验。云顶新耀已打造多款疾病首创或者同类最佳的药物组合，公司的治疗领域包括肾科疾病、感染性和传染性疾病、自身免疫性疾病。有关更多信息，请访问公司网站：www.everestmedicines.com。前瞻性声明本新闻稿所发布的信息中可能会包含某些前瞻性表述，乃基于本公司或管理层在做出表述时对公司业务运营情况及财务状况的现有看法、相信、和现有预期，可能会使用"将"、"预期"、"预测"、"期望"、"打算"、"计划"、"相信"、"预估"、"确信"及其他类似词语进行表述。这些前瞻性表述并非对未来业绩的保证，会受到风险、不确定性及其他因素的影响，有些乃超出本公司的控制范围，难以预计。因此，受我们的业务、竞争环境、政治、经济、法律和社会情况的未来变化及发展等各种因素及假设的影响，实际结果可能会与前瞻性表述所含资料有较大差别。本公司及各附属公司、各位董事、管理人员、顾问及代理未曾且概不承担更新该稿件所载前瞻性表述以反映在本新闻稿发布日后最新信息、未来项目或情形的任何义务，除非法律要求。参考文献：1.利妥昔单抗在膜性肾病中应用的专家共识，中华内科杂志2022年3月第61卷第3期。 Copyright 2024 亚太商讯 via SeaPRwire.com.

- Patients in the low-dose cohort who have completed 36 weeks of treatment, 9 out of 11 (81.8%) achieved overall clinical remission and 10 out of 11 (91%) achieved immunological complete remission.- In the high dose cohort, 6 out of 7 (85.7%) patients achieved overall clinical remission and all patients achieved immunological complete remission by week 24.- EVER001 was generally safe and well tolerated. No clinically significant adverse events typically associated with earlier-generation BTK inhibitors, such as bleeding, arrhythmia, severe infection, leukopenia, thrombocytopenia, or severe liver function impairment, were reported.SHANGHAI, Dec 4, 2024 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK,“Everest”, or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced positive results in the ongoing Phase 1b/2a clinical trial for the treatment of primary membranous nephropathy (pMN) with EVER001 (previously known as XNW1011), a next-generation covalent reversible Bruton's tyrosine kinase (BTK) inhibitor. In an analysis of the data available as of September 13th, 2024, results from the Phase 1b/2a clinical trial showed that for patients in the low-dose cohort who have completed 36 weeks of treatment, 9 out of 11 (81.8%) achieved overall clinical remission1 and 10 out of 11 (91%) achieved immunological complete remission (ICR)2. In the high dose cohort, 6 out of 7 (85.7%) patients achieved overall clinical remission and all patients achieved ICR by week 24.EVER001 is a covalent reversible BTK inhibitor with potentially best-in-class characteristics for the treatment of autoimmune renal diseases. Compared to covalent irreversible BTK inhibitors, EVER001 offers improved selectivity while maintaining high potency, thereby potentially avoiding many of the side effects associated with earlier-generation BTK inhibitors. Everest Medicines holds global rights to EVER001 for the treatment of renal diseases.The Phase 1b/2a clinical trial of EVER001 for the treatment of pMN is an ongoing trial conducted in China. A total of 31 patients with biopsy-proven pMN who tested positive for anti-PLA2R autoantibodies were enrolled into two cohorts. The total treatment duration was 36 weeks. Based on the patient data collected by September 13th, 2024, in the low-dose cohort, the geometric least squares mean 24-hour proteinuria decreased by 78.3% at week 36 compared to baseline, while the high-dose cohort achieved a 73.8% reduction by week 24. EVER001 treatment induced greater than 90% reductions in anti-PLA2R antibody as early as week 24 in the low-dose cohort and week 12 in the high-dose cohort. EVER001 was generally safe and well tolerated. No clinically significant adverse events typically associated with earlier-generation BTK inhibitors, such as bleeding, arrhythmia, severe infection, leukopenia, thrombocytopenia, or severe liver function impairment, were reported."We are excited to see the encouraging results in this preliminary analysis of our Phase 1b/2a clinical proof-of-concept trial of EVER001. This demonstrates the potential of EVER001 as a next-generation BTK inhibitor for the treatment of various autoimmune renal diseases, including pMN. "Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines, said："This data release marks the first time Everest Medicines has disclosed results from its global pipeline. We look forward to completing this trial and sharing detailed data in future conferences and publications. Moving forward, we will continue to drive the global clinical development of EVER001, to meet patients' urgent clinical needs.”Membranous nephropathy is a common pathological type of nephrotic syndrome in adults, and its prevalence in China has been increasing, ranking second only to IgA nephropathy3. There are about 2 million patients with pMN in China, with an estimated 80,000 to 100,000 patients in the United States, 80,000 in Europe, and 40,000 in Japan. There are no approved drugs for this indication worldwide. The current treatment goal is to improve remission rates, reduce high relapse rates, and minimize the risk of chronic toxicity caused by currently available treatments. More than one-third of pMN patients still progress to end-stage renal disease under current standards of care.This Phase 1b/2a clinical trial was approved by the Center for Drug Evaluation of the National Medical Products Administration in September 2022 to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of EVER001 in Chinese patients with glomerular diseases characterized by proteinuria. The previously published results of a Phase 1 study conducted in healthy Chinese and Australian subjects conducted by SinoMab BioScience indicate that EVER001 has high selectivity, excellent pharmacokinetic properties, a good safety profile, and strong target binding.About EVER001EVER001 (previously known as XNW1011) is a next-generation covalent reversible Bruton's tyrosine kinase (BTK) inhibitor in development globally for the treatment of renal diseases. BTK is an essential component of the B-cell receptor signaling pathways that regulate the survival, activation, proliferation, and differentiation of B lymphocytes. Targeting BTK with small molecule inhibitors has been demonstrated to be an effective treatment option for B-cell lymphomas and autoimmune diseases. Based in part on results from a completed phase 1 trial with healthy subjects conducted by SinoMab in China, EVER001 exhibited high selectivity, excellent pharmacokinetics properties, strong target binding and a safety profile that supports continued clinical development.Under an exclusive licensing agreement with Sinovent Pharmaceuticals and SinoMab BioScience, Everest owns global rights to develop, produce and commercialize EVER001 for the treatment of renal diseases.Investor Calls InformationEverest Medicines will hold investor calls on the data results from EVER001 Phase 1b/2a clinical study in primary membranous nephropathy. EVER001 is a next-generation covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor, and Everest owns the global rights to develop EVER001 for the treatment of renal diseases.The English session of the conference call will be held at 9:00 AM on Dec. 4, 2024, Beijing Time (8:00 PM U.S. Eastern Time on Dec. 3, 2024) and the Mandarin session of the conference call will be held at 10:30 AM Beijing Time on the same day (9:30 PM U.S. Eastern Time on Dec. 3, 2024).The conference calls can be accessed by the following links:For English Session:Time: 9:00 AM Beijing Time, Wednesday, Dec. 4, 2024 (8:00 PM U.S. Eastern Time on Dec. 3, 2024)Pre-Registration Link: https://www.acecamptech.com/eventDetail/60510700Webcast Link:https://www.acecamptech.com/meeting_live/70512679/774680?event_id=60510700Alternatively, participants may dial in to the conference call using below dial-in information:United States: +1-646-2543594 (EN)Chinese Mainland: +86-10-58084166 (EN), +86-10-58084199 (CN)Hong Kong, China: +852-30051313 (EN), +852-30051355 (CN)United Kingdom: +44-12-1368-0466 (EN)International: +1-866-6363243 (EN)Password: 842080For Mandarin Session:Time: 10:30 AM Beijing Time, Wednesday, Dec. 4, 2024 (9:30 PM U.S. Eastern Time on Dec. 3, 2024)Webcast Link: https://s.comein.cn/n3arj55sAlternatively, participants may dial into the conference call using below dial-in information:United States: +1-646-3578788, +1-408-7093255Chinese Mainland: 400-969-8928, 400-806-3263Hong Kong, China: +852-301-83602Taiwan, China: +886-226563394, +886-277417882Singapore: +65-64075649, +65-66220840United Kingdom: +44-2070970018 International: +86-2362737123Password: 377570The replay of English session will be available shortly after the call and can be accessed by visiting the Company’s website at http://www.everestmedicines.com.About Everest MedicinesEverest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company’s core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders. For more information, please visit its website at www.everestmedicines.com.Forward-Looking Statements:This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.References:1.Overall clinical remission (complete remission or partial remission): 24h proteinuria complete remission (CR): 24h proteinuria < 0.3g/24 h; 24h proteinuria partial remission (PR): 24h proteinuria < 3.5g/24h, but ≥0.3g/24 h, and reduction > 50%, regardless of eGFR or the serum albumin level from baseline.2. Immunological complete remission (ICR): anti-PLA2R titer < 20RU/ml (negative).3. Expert consensus on the application of rituximab in the treatment of membranous nephropathy, Chin J Intern Med, March 2022, Vol. 61, No. 3. Copyright 2024 ACN Newswire via SeaPRwire.com.

SINGAPORE, Dec 4, 2024 - (ACN Newswire via SeaPRwire.com) - OKX, the leading cryptocurrency exchange, has partnered with DeAgentAI, the first AI-driven feedback incentive protocol in Web3, to launch an exclusive airdrop campaign. Starting December 3rd, users can complete simple tasks on OKX Wallet to win a share of $50,000 worth of DA tokens.Click here to join the campaign: https://www.okx.com/web3/giveawayParticipating in the DeAgentAI and OKX Wallet airdrop is easy. Download the OKX Wallet, follow DeAgentAI social media networks, and complete a few simple tasks such as sharing campaign posts, and you can claim your rewards. The campaign runs from December 3rd for two weeks-don't miss out!This collaboration brings users unparalleled opportunities to explore advanced AI technology while enjoying the benefits of a secure and user-friendly wallet. With rewards of $50,000 worth of DA tokens, the initiative encourages users to explore Web3 in an innovative and incentivized environment. DeAgentAI and OKX Wallet aim to foster adoption and empower users in the rapidly evolving crypto space.About DeAgentAIDeAgentAI is a trailblazer in Web3 technology, introducing the first AI feedback mechanism incentive protocol that achieves "proof of insight" by integrating user feedback into the model training process. Its flagship product, AlphaX, combines advanced MOE and Transformer architectures to predict BTC and ETH price trends with over 80% accuracy.What is OKX's Web3 Wallet?OKX Wallet complements this innovation with its secure and user-friendly interface tailored for decentralized finance (DeFi) and Web3 applications. As a leading wallet in the crypto space, OKX Wallet enables seamless integration with platforms like DeAgentAI, empowering users to engage in token giveaways, explore cutting-edge AI tools, and participate in the rapidly growing Web3 ecosystem.Contact InformationYves-Alexandre d'OuradouFounderdeagent.ai@gmail.com(001) 2024989991Source: DeAgentAI Copyright 2024 ACN Newswire via SeaPRwire.com.

SAN DIEGO, CA, Dec 4, 2024 - (ACN Newswire via SeaPRwire.com) - The Japan Maritime Self-Defense Force (JMSDF) has selected the General Atomics Aeronautical Systems, Inc. (GA-ASI) SeaGuardian® Remotely Piloted Aircraft (RPA) systems for its Long Endurance Unmanned Aerial Vehicle program. This follows JMSDF use of SeaGuardian since May 2023 as part of its Medium-Altitude, Long Endurance (MALE) RPA System Trial Operations Project.SeaGuardian has been used by JMSDF to conduct various tests including whether unmanned aircraft can supplant some of the missions currently accomplished with manned aircraft. SeaGuardian is a MALE RPA system that can fly for 24 hours or more, depending on the configuration.GA-ASI has strengthened its Maritime Wide Area Surveillance (MWAS) for Japan with Optix+, which gathers information from the SeaGuardian sensors, as well as other data sources, displaying the full picture of surveillance information for its operator. This functionality makes it easy to task and direct its Intelligence, Surveillance and Reconnaissance (ISR) information in real time. GA-ASI's Optix+ software suite rapidly correlates and exploits collected data into an easily shared common operational picture. Having multi-source correlated data enables automatic detection of anomalous behaviors over waters.SeaGuardian features two multi-mode maritime surface-search radars with an Inverse Synthetic Aperture Radar (ISAR) imaging mode, an Automatic Identification System (AIS) receiver, and a High-Definition - Full-Motion Video sensor equipped with optical and infrared cameras as well as electronic intelligence receivers. This sensor suite enables real-time detection and identification of surface vessels over thousands of square nautical miles and provides automatic tracking of maritime targets and correlation of AIS transmitters with radar and electronic intelligence tracks.About GA-ASIGeneral Atomics Aeronautical Systems, Inc. (GA-ASI), an affiliate of General Atomics, is a leading designer and manufacturer of proven, reliable RPA systems, radars, and electro-optic and related mission systems, including the Predator® RPA series and the Lynx® Multi-mode Radar. With more than eight million flight hours, GA-ASI provides long-endurance, mission-capable aircraft with integrated sensor and data link systems required to deliver persistent situational awareness. The company also produces a variety of sensor control/image analysis software, offers pilot training and support services, and develops meta-material antennas.For more information, visit www.ga-asi.com .Avenger, Lynx, Predator, Reaper, SeaGuardian, and SkyGuardian are registered trademarks of General Atomics Aeronautical Systems, Inc.Contact InformationGA-ASI Media Relationsasi-mediarelations@ga-asi.comSource: General Atomics Aeronautical Systems, Inc. Copyright 2024 ACN Newswire via SeaPRwire.com.

Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - December 3, 2024) - Military Metals Corp. (CSE: MILI) (OTCQB: MILIF) (FSE: QN90) (the "Company" or "MILI") a leading North American exploration company focused on critical minerals, acknowledges today's announcement by China banning exports of gallium, germanium, and antimony to the United States. This move underscores the urgent need for Western nations to secure reliable long-term sources of these essential materials.Antimony, a critical component in military applications, energy storage, and advanced manufacturing, is now at the forefront of the global supply chain crisis. China's ban, coupled with existing restrictions that came into effect September 15, 2024, has already sent antimony prices soaring by over 228% this year(1). The Western world faces mounting pressure to address its reliance on China for strategic resources critical to national defense and technological innovation. This ban comes at a time when defense sector inventories are at already concerningly low levels.(2)Military Metals recent antimony mineral project acquisitions in Slovakia, Nova Scotia, and Nevada provide shareholders with a pure antimony play with a diverse portfolio in top jurisdictions."This announcement from China reinforces the importance of Military Metals' mission to secure a sustainable, independent future supply chain for critical minerals," said Scott Eldridge, CEO of Military Metals Corp. "The West can no longer afford to rely on adversarial nations for resources essential to our security and economic stability. We are taking proactive steps to meet this growing demand with future domestic and allied sources of antimony."As geopolitical tensions escalate and the trade war intensifies, Military Metals will continue to prioritize the development of critical mineral resources and work closely with governments and industry partners to ensure the West remains resilient and self-sufficient.About Military Metals Corp. The Company is a British Columbia-based mineral exploration company that is primarily engaged in the acquisition, exploration and development of mineral properties with a focus on antimony.ON BEHALF OF THE BOARD of DIRECTORSFor more information, please contact:Scott EldridgeCEO and Directorscott@militarymetalscorp.comFor enquiries, please call 604-722-5381 or 604-537-7556This news release contains "forward-looking information". Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking information in this news release include exploration activities, and assumptions related to the continuation of the global demand for antimony. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this news release. These include, geopolitical developments related to the supply of antimony, the continued use of antimony and availability of alternatives, availability of capital and labour in respect of the properties that are the subjects of this news release, the results of any future exploration activities, which cannot be guaranteed, and such other factors as may impact both and any future activities in respect of the properties.. Additional risk factors can also be found in the Company's public filings under the Company's SEDAR+ profile at www.sedarplus.ca. Forward-looking statements contained herein are made as of the date of this news release and the Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward looking statements if circumstances, management's estimates or opinions should change, except as required by securities legislation. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements.The Canadian Securities Exchange has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.(1)Reuters; China bans export of critical minerals to US as trade tensions escalate; By Amy Lv and Tony Munroe; December 3, 2024(2)Heritage Foundation: commentary/It’s Past Time to Re-Supply Our Munitions-Depleted U.S. Navy by Jim Fein; June 17, 2024To view the source version of this press release, please visit https://www.newsfilecorp.com/release/232325 Copyright 2024 ACN Newswire via SeaPRwire.com.